Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease

The Company was Granted Approval for an Additional 48 sites Across Five European Union Countries

Annovis Currently has 50 Clinical Trial Sites Open in the United States

See more here